

October 28, 2026

1. **The Manager-Listing**
National Stock Exchange of India Limited
(Scrip Symbol: NAUKRI)
2. **The Manager-Listing**
BSE Limited
(Scrip Code: 532777)

Dear Sir/Madam,

Subject: Outcome of the Board Meeting – October 28, 2026

Ref.: Intimation pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to the requirements of Regulation 30 read with Schedule III of the Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. on Wednesday, October 28, 2026, have, inter alia, considered and approved the following:

- a) Proposal to divest its entire holding (i.e. 14.18%) held in Medcords Healthcare Solutions Private Limited ('Medcords') on fully converted & diluted basis, through its wholly-owned subsidiary, Startup Investments (Holding) Limited (SIHL). A provision for impairment of full amount against said investment was booked in FY 2023-24.

Post this divestment, Medcords will cease to be Joint Venture of the Company.

- b) Proposal to divest its entire holding (i.e. 31.64%) held in Unnati Online Private Limited ('Unnati Online') on fully converted & diluted basis (excluding ESOP Pool), through its wholly-owned subsidiary, Startup Investments (Holding) Limited (SIHL). A provision for impairment of full amount against said investment was booked in FY 2019-20.

Post this divestment, Unnati Online will cease to be Associate Company of the Company.

- c) Investment of an amount of about Rs. 150 crores in Redstart Labs (India) Limited, wholly owned subsidiary of the Company.
- d) Basis the recommendation of the Nomination & Remuneration Committee, reconstitution of the Audit Committee (AC), by inducting Mr. Naresh Chand Gupta, Additional Director (Independent Category), as a member of the Committee, with effect from October 29, 2026. Post reconstitution, the composition of AC with effect from October 29, 2026 shall be as under:

S.No.	Name of the Member	Category	Position in the Committee
1.	Mr. Sanjiv Sachar	Independent Director	Chairman
2.	Ms. Geeta Mathur	Independent Director	Member
3.	Ms. Radha Rajappa	Independent Director	Member
4.	Mr. Naresh Chand Gupta	Independent Director	Member

infoedge

Further, the details as required in terms of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 in relation to the above referred items with respect to divestment and investment are enclosed as Annexure A to this intimation.

The exchanges are also informed that the Board Meeting commenced at 10:30 a.m. and the aforesaid items have been considered and approved by the Board at 12:20 p.m. The same are hereby furnished to the Stock Exchanges, while the meeting continues for considering remaining agenda items at the time of this intimation and is expected to end around 01:30 p.m.

This intimation is also being uploaded on Company's website and can be accessed at www.infoedge.in.

We request you to kindly take the above on record.

Thanking You.

Yours faithfully,
For **Info Edge (India) Limited**

Jaya Bhatia
Digitally signed by
Jaya Bhatia
Date: 2026.10.28
12:39:40 +05'30'

Jaya Bhatia
Company Secretary & Compliance Officer

Encl.: as above

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

a) Divestment of Company's Stake held in Medcords Healthcare Solutions Private Limited through wholly owned subsidiary, Startup Investments (Holding) Limited (SIHL)

S. No.	Particulars	Details												
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Name: Medcords Healthcare Solutions Private Limited ('Medcords') <table border="1"> <thead> <tr> <th colspan="3">Details as on March 31, 2026*</th></tr> <tr> <th></th><th>Amount (Rs. in crores)</th><th>Percentage</th></tr> </thead> <tbody> <tr> <td>Total Income</td><td colspan="2" rowspan="4">NIL</td></tr> <tr> <td>Networth</td></tr> <tr> <td>Turnover</td></tr> <tr> <td>Revenue</td></tr> </tbody> </table> <i>*A provision for impairment of full amount against investment in Medcords was booked in FY 2023-24. Accordingly, Medcords has not contributed to any of the relevant financial parameters, including Total Income, Net Worth, Turnover and Revenue, in the consolidated financial statements of the Company for FY 2025-26. Therefore, the amounts and corresponding percentages attributable to Medcords in respect of the aforesaid financial parameters for FY 2025-26 have been mentioned as Nil.</i>	Details as on March 31, 2026*				Amount (Rs. in crores)	Percentage	Total Income	NIL		Networth	Turnover	Revenue
Details as on March 31, 2026*														
	Amount (Rs. in crores)	Percentage												
Total Income	NIL													
Networth														
Turnover														
Revenue														
2.	Date on which the agreement for sale has been entered into	The agreement for sale shall be entered into within 30 days from the Board's approval.												
3.	The expected date of completion of sale/disposal	The transaction of sale/disposal/divestment of the Company's stake held in Medcords on fully converted and diluted basis i.e. 14.18% through its wholly-owned subsidiary SIHL, has been approved by the Board of Directors of the Company in its meeting held today, i.e. on October 28, 2026. The Company will submit an update on the aforesaid sale/disposal which is expected to be completed by January 27, 2027.												
4.	Consideration received from such sale/disposal	About Rs. 5000.												

5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	The aforesaid Shareholding will be sold to Mr. Shreyans Mehta, Director and Promoter of Medcords. Mr. Shreyans Mehta is Promoter and Director of Medcords. The buyer is not related to promoter/promoter group/group companies of the Company.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms length”	Transaction is not a Related Party Transaction for the Company.
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not Applicable.
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable.

b) Divestment of Company’s Stake held in Unnati Online Private Limited through wholly owned subsidiary, Startup Investments (Holding) Limited (SIHL)

S. No.	Particulars	Details												
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Name: Unnati Online Private Limited (‘Unnati Online’) <table border="1"> <thead> <tr> <th colspan="3">Details as on March 31, 2026*</th></tr> <tr> <th></th><th>Amount (Rs. in crores)</th><th>Percentage</th></tr> </thead> <tbody> <tr> <td>Total Income</td><td colspan="2" rowspan="4">NIL</td></tr> <tr> <td>Networth</td></tr> <tr> <td>Turnover</td></tr> <tr> <td>Revenue</td></tr> </tbody> </table> <i>*A provision for impairment of full amount against investment in Unnati Online was booked in FY 2019-20. Accordingly, Unnati Online has not contributed to any of the relevant financial parameters, including Total Income, Net Worth, Turnover and Revenue, in the consolidated financial statements of the Company for FY 2025–26. Therefore, the amounts and corresponding percentages attributable to Unnati Online in respect of the aforesaid financial parameters for FY 2025–26 have been mentioned as Nil.</i>	Details as on March 31, 2026*				Amount (Rs. in crores)	Percentage	Total Income	NIL		Networth	Turnover	Revenue
Details as on March 31, 2026*														
	Amount (Rs. in crores)	Percentage												
Total Income	NIL													
Networth														
Turnover														
Revenue														
2.	Date on which the agreement for sale has been entered into	The agreement for sale shall be entered into within 30 days from the Board’s approval.												

3.	The expected date of completion of sale/disposal	The transaction of sale/disposal/divestment of the Company's stake held in Unnati Online on fully converted and diluted basis (excluding ESOP Pool) i.e. 31.64% through its wholly-owned subsidiary SIHL, has been approved by the Board of Directors of the Company in its meeting held today, i.e. on October 28, 2026. The Company will submit an update on the aforesaid sale/disposal which is expected to be completed by January 27, 2027.
4.	Consideration received from such sale/disposal	About Rs. 5000.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	The aforesaid Shareholding will be sold to Mr. Eral Ravi and Mr. Aashutosh Chaudhary, Directors and Promoters of Unnati Online. Mr. Eral Ravi and Mr. Aashutosh Chaudhary are Promoters and Directors of Unnati Online. The buyers are not related to promoter/promoter group/group companies of the Company.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	Transaction is not a Related Party Transaction for the Company.
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not Applicable.
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable.

c) Investment in Redstart Labs (India) Limited, wholly owned subsidiary of the Company:

Sl. No.	Particulars	Details									
1.	Name of the target entity, details in brief such as size, turnover etc.	Redstart Labs (India) Limited ('Redstart') Address: Ground Floor, 12A, 94, Meghdoot, Nehru Place, New Delhi - 110019 <table border="1"> <thead> <tr> <th colspan="3">Details as on March 31, 2026 (Rs. in crores)</th></tr> <tr> <th>Turnover</th><th>PAT</th><th>Networth</th></tr> </thead> <tbody> <tr> <td>Nil</td><td>(2.99)</td><td>76.93</td></tr> </tbody> </table>	Details as on March 31, 2026 (Rs. in crores)			Turnover	PAT	Networth	Nil	(2.99)	76.93
Details as on March 31, 2026 (Rs. in crores)											
Turnover	PAT	Networth									
Nil	(2.99)	76.93									
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The Company already holds 100% stake in Redstart on a fully converted and diluted basis. Accordingly, it is a wholly owned subsidiary of the Company in accordance with the Companies Act, 2013 and hence falls in the category of a related party as on the date of making this investment. Promoter/Promoter Group/Group Companies of the Company have no interest in the said investment. The said transaction is with wholly owned subsidiary of the Company. Accordingly, the arm's length requirement is not applicable.									
3.	Industry to which the entity being acquired belongs	Redstart is engaged in the business of direct or indirect investments in tech companies and providing all types of Internet services, development of software, consultancy, technical support for consumer companies, internet or SAAS providers, and any other services in the area of information technology and product development.									
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This investment is being done to meet the working capital requirements, explore investment opportunities and other general purposes.									
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable									
6.	Indicative time period for completion of acquisition	Within 18 months from the approval.									
7.	Consideration- whether cash consideration or share swap or any other form and details of the same.	Cash Consideration									
8.	Cost of acquisition and/or the price at which the shares are acquired.	About Rs. 150 crores									
9.	Percentage of shareholding/control acquired and/ or number of shares acquired.	The Company has agreed to acquire Equity Shares of face value of Rs. 10 each for an aggregate consideration of upto Rs. 150 crores, in one or more tranches depending upon fund									

		requirements of Redstart. Post this investment, Redstart remains the wholly-owned subsidiary of the Company.						
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	<u>Brief Background:</u> Redstart is engaged in the business of direct or indirect investments in tech companies and providing all types of Internet services, development of software, consultancy, technical support for consumer companies, internet or SAAS providers, and any other services in the area of information technology and product development. <u>Date of Incorporation:</u> July 7, 2020 <u>Country in which the acquired entity has presence:</u> India <u>Last three years turnover:</u> <table> <tr> <th>2025-26</th><th>2024-25</th><th>2023-24</th></tr> <tr> <td>Nil</td><td>Nil</td><td>Nil</td></tr> </table>	2025-26	2024-25	2023-24	Nil	Nil	Nil
2025-26	2024-25	2023-24						
Nil	Nil	Nil						